# Medical Oncology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Edward W. Brooke (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML014-SYN-TD
- Date: 2003-02-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Mei-Ling Cho, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Howard Bellamy, MD

## Reason for consultation

Man of 83 with stage IIA, hormone receptor-positive, HER2-negative right breast cancer, fourteen weeks after bilateral mastectomy and right axillary dissection, on tamoxifen for eleven weeks, started at another hospital. Please take over his adjuvant endocrine therapy, confirm the adjuvant plan, and arrange germline genetic testing. **S**

## History

Mr. Brooke is seen at the request of Dr. Bellamy to take over his breast cancer care. He noticed discomfort in his right breast, which he dismissed for a time, before imaging and biopsy showed cancer; he says he did not know men could get breast cancer. He had a bilateral mastectomy and right axillary dissection at another hospital about four months ago, and started tamoxifen four weeks later. He has taken it daily for fifteen weeks with mild night hot flashes and no other effects. He has no bone pain, cough, headache, or weight loss. He is independent, walks most days, and has no history of blood clots, stroke, or liver disease. **S**

## Examination

| System | Finding |
|---|---|
| General | Well |
| Chest wall | Healed transverse mastectomy scars on both sides; no nodule or skin change |
| Lymph nodes | No axillary, supraclavicular, or cervical nodes on either side |
| Extremities | Upper arm circumference 31 cm on both sides; no calf swelling or tenderness |
| Abdomen | Soft; liver not enlarged |

BP 130/74 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 81.8 kg; BMI 24.4 kg/m². All vital signs are synthetic.

## Data reviewed

Outside imaging reports (bilateral diagnostic mammography and bilateral breast and axillary ultrasound), biopsy and surgical pathology with ER, PR, HER2, and Ki-67; the first-visit blood count, chemistry, and 25-hydroxyvitamin D; and the DXA scan from this morning (femoral neck T-score -1.2, lumbar spine -0.4). Femoral neck T-score (DXA): -1.2 (low); Lumbar spine T-score (DXA): -0.4; PHQ-2: 0. All results are synthetic.

## Assessment

1. **Right breast cancer, pT1c pN1a M0, stage IIA, ER and PR positive, HER2 negative, grade 2** (C50.121). Breast cancer in men is less common than in women but is biologically similar, and most cases are hormone receptor-positive, as his is. With one small nodal metastasis, a strongly ER-positive grade 2 tumor, and his age of 83, endocrine therapy gives most of the benefit. The added gain from chemotherapy would be small and its harms greater at his age. Radiation after mastectomy for one involved node is a choice with a small gain in local control; with clear margins and no extranodal spread, omitting it is reasonable, and I agree with the decision made after surgery. No staging scans are needed without symptoms. **S**
2. **Adjuvant tamoxifen** (Z79.810). Tamoxifen is the preferred adjuvant endocrine therapy for men. An aromatase inhibitor alone does not suppress estrogen adequately in men and is not recommended; it would be used only with a GnRH agonist if tamoxifen could not be taken. His mild hot flashes are common in men on tamoxifen. The main serious risk at his age is venous thromboembolism; he has no history of clots. **S**
3. **Germline genetic testing**. Genetic counseling and germline testing should be offered to every man with breast cancer, whatever his age or family history. BRCA2 is the gene most often involved; a pathogenic variant would raise his risk of prostate and pancreatic cancer and would mean his relatives should be offered testing. **S**
4. **Bone health**. Low bone mass at the femoral neck with mild vitamin D insufficiency. His fracture risk does not call for a bone drug. Bone-modifying drugs should not be given to prevent recurrence of early breast cancer in men, but can be used if osteoporosis develops. **S**

## Recommendations

1. Continue tamoxifen 20 mg daily for an initial five years; at five years, if he tolerates it, discuss five more years given the involved node. Do not switch to an aromatase inhibitor alone.
2. No chemotherapy and no radiation now.
3. Genetic counseling and a germline multigene panel (BRCA2, BRCA1, PALB2, CHEK2, ATM, and others), sent today; if a variant is found, a letter for relatives offering them testing, and prostate and pancreatic screening for him.
4. Tamoxifen safety at each visit: symptoms of leg or lung clots, mood, hot flashes, sexual side effects such as lower libido or erectile problems, and adherence; avoid paroxetine, fluoxetine, and bupropion, which block its activation; report any change in vision.
5. Surveillance: history and examination of both sides of the chest wall and both axillae every 3 to 6 months for 3 years, then every 6 to 12 months to 5 years, then yearly. No mammography, because both breasts were removed, and no routine blood tests, tumor markers, or scans without symptoms.
6. Bone health: vitamin D 1000 units daily with a recheck in three months, calcium from food, weight-bearing exercise, and DXA every two years.
7. Lymphedema risk reduction for the right arm and a written survivorship care plan within the first year.

## Strengths and supports

- Supports: family and a wide circle of friends and former colleagues **S**

## Communication

Discussed with Dr. Bellamy today. The patient agrees with the plan. He asked that his diagnosis be kept private for now, and that wish is recorded. **S**

## Follow-up

Medical oncology every six months and at five years for the decision on extending tamoxifen. Genetic counseling for the germline result. Primary care continues tamoxifen safety checks, distress screening, bone health, and survivorship visits every three months. **S**

## Guideline basis

- Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020), American Society of Clinical Oncology
- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025), National Comprehensive Cancer Network
- Bedrosian I, et al. Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol 2024;42(5):584-604 (2024), American Society of Clinical Oncology and Society of Surgical Oncology
- Shapiro CL, et al. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline (2019), American Society of Clinical Oncology
- CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026), Aether Forge
